Ernexa Therapeutics/$ERNA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ernexa Therapeutics
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
- Ticker
- $ERNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6
- Headquarters
- Cambridge, United States
- Website
- www.ernexatx.com
ERNA Metrics
BasicAdvanced
$3.2M
-
-$14.93
-
-
Price and volume
Market cap
$3.2M
52-week high
$15.88
52-week low
$1.74
Average daily volume
48K
Financial strength
Current ratio
2.574
Quick ratio
2.155
Long term debt to equity
0.032
Total debt to equity
0.071
Interest coverage (TTM)
-474.22%
Profitability
EBITDA (TTM)
-12.764
Effective tax rate (TTM)
0.73%
Management effectiveness
Return on assets (TTM)
-120.56%
Return on equity (TTM)
-352.43%
Valuation
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-0.168
Free cash flow yield (TTM)
-595.13%
Free cash flow per share (TTM)
-11.486
Growth
Earnings per share change (TTM)
-84.26%
3-year earnings per share growth (CAGR)
-78.69%
ERNA Financial Performance
Revenues and expenses
ERNA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.